

Nonclinical Topics



Working Group Scope

A collaboration working to improve nonclinical assessments and regulatory science by identifying key needs and challenges in the field and then establishing an innovative framework for addressing them in a collaborative manner through limited term projects.

Our focus is on using informatics approaches and standards for delivering ideas and solutions to nonclinical data challenges. Annually, at the Computational Sciences Symposium (CSS), we present our progress and achievements and develop new projects that further the value of nonclinical data.

[Conformance with the tumor.xpt Specification](#)

[Nonclinical Study Data Reviewer's Guide](#)

[SEND Implementation User Group](#)

[SEND Industry Feedback Survey](#)

[Supporting the Use of SEND for the Implementation of Virtual Control Groups](#)

Current Projects

Resources

Click [here](#) to search for all Nonclinical Topics deliverables, past projects are housed under the [archived section](#).

For Reference

[Nonclinical Scripts](#)

[Harmonization of SEND Implementation to Enable Historical Control Data Analysis](#)



Working Group Lead
Susan DeHaven

susan.dehaven@sanofi.com

Susan DeHaven is a veteran of SEND standard development and implementation. She and her global team manage administration of software applications used across multiple countries for data collection, analysis, visualization and reporting, along with the associated standards governance and data management for analysis and submission. Most recently, Susan and her team have implemented data systems with tools and repositories for transforming data from sources to SEND and SDTM. Susan is a co-Lead, with FDA partners, of the PhUSE Nonclinical Topics Working Group and the CDISC/FDA SEND for CBER Initiative and is a long time member of the CDISC SEND Core Team. She has represented her opinions about pharma industry perspectives on SEND in various conference panels and has been recognized with a Collaboration Award from FDA and a PhUSE /FDA Working Group Award for Achievement. Susan is based in Bridgewater, New Jersey, USA is an avid equestrian and foxhunter, and lives on a farm in Asbury, New Jersey.



Working Group Lead
Kevin Snyder

kevin.snyder@fda.hhs.gov

Dr. Kevin Snyder manages data science and informatics initiatives to support the pharmacology /toxicology review staff in the Office of New Drugs in the Center for Drug Evaluation and Research at the US FDA. These initiatives include research efforts to develop methods to optimize the regulatory use of standardized electronic CDISC-SEND-formatted toxicology study data as well as the development of software solutions to improve the efficiency of research and review activities conducted by the pharmacology /toxicology review staff. Dr. Snyder also leads an agency-wide Data Science and Software Development working group that is focused on building out the internal infrastructure necessary to support the work of data scientists across the agency and is an active collaborator with several consortia efforts, e.g. CDISC, PHUSE, and BioCelerate, to improve the implementation and use of the SEND data standard. Dr. Snyder received his Bachelors in biochemistry from the University of Maryland in 2008 and his PhD in neuroscience from the University of Pennsylvania School of Medicine in 2013.



Working Group Lead
Michael Denieu

michael.denieu@covance.com

Michael is a member of Global Data Science Solutions at Labcorp, joining the team as an associate generating and QCing SEND data. He is moving to a supervisor in 2020. He has been on the quality of data science and has been on the quality of data science initiatives to provide enhancements to the data science capabilities, as well as working with the team to meet their needs and expectations are met. He is a volunteer with CDISC and an active member of the domain sub-team. Michael's original interest in evolutionary biology and quantitative programming and statistical skills during his graduate work and post-graduate work contributed to develop an interest in the use of data which led Michael to Labcorp.